Other

Lubris LLC

Rhode Island Hospital

Jawed Fareed

Benjamin D Sullivan

Gregory D Jay

Umberto Cornelli

Khaled Elsaid

Roman Krawetz

Luigi De Ambrosi

John Lee

Stanley Lorens

Israel Hanin

Ronald Mervis

Tannin Avery Schmidt

Tannin A Schmidt

Edward R Truitt, Iii

Edward R Truitt

Adam Chodobski

Joanna Szmydynger-Chodobska

Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-&#x3ba;B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.

Use of PRG4 as an anti-inflammatory agent

The present invention relates to the use of glycosaminoglycan fractions having an average molecular weight of 2400 (&#xb1;200) D for the preparation of pharmaceutical compositions suitable for the treatment of emotional dysfunctions, especially depressive disorders, anxiety disorders, anxiety neurosis, agitation, confusion.

Glycosaminoglycans for treatment of emotional dysfunctions

The present invention relates to the use of glycosaminoglycans having an average/molecular weight of 2,400 D for the preparation of pharmaceutical compositions suitable for the treatment of senile dementia, in particular for the treatment of Alzheimer's disease or SDAT (Senile Dementia Alzheimer's Type) and of the cerebral neurological lesions from ictus and from traumas.

Glycosaminoglycans having an average molecular weight of 2400 D suitable for the treatment of senile dementia

Growing community of inventors

Westchester, IL, United States of America

Jawed Fareed